SAU:4019

Specialized Medical Company · SAU · Healthcare · SAR · FY for 2025

Figures on this page computed 2026-11-08 12:27 UTC

Last close

n/aSAR

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

12.4xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
13.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
17.3%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
14.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.70Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed

Safety is the furthest below its sector's middle: 0.49 against 0.57 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.17x

1.71x

2.22x

0.84x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.17x
Its own average over 5 years, 1.32B.
Profit1.71x
Its own average over 5 years, 155.6M.
Free cash flow2.22x
Its own average over 5 years, 103.0M.
Debt0.84x
Its own average over 5 years, 986.1M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 2.22 times.

The filed years, as a table

Each line is 100 at 2021-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2021-12-31	100.0	100.0	100.0
2022-12-31	114.7	183.9	100.0
2023-12-31	129.8	301.3	100.0
2024-12-31	136.7	330.8	100.0
2025-12-31	146.3	476.3	100.0

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: SAR

How profit was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: SAR

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: SAR

Figures behind the shape

Growth

44.0%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
One-year change in net income44.0%
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed

Returns on capital

13.4%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital13.4%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity22.4%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets11.1%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

24.9%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin24.9%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin15.8%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin17.3%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin14.8%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

12.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings12.4x
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
Price to book2.8x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA9.3x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio2.1x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

0.70

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.70
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.42
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage4.8x
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score3.24
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.